Hexagon Bio

Hexagon Bio is a biopharmaceutical company focused on discovering new medicines by leveraging the vast potential of the global metagenome. Their interdisciplinary platform combines data science, genomics, synthetic biology, and automation to systematically mine microbial genomes for novel chemical compounds linked to protein targets. These evolved molecules have the potential to offer unique solutions to complex human diseases, particularly in areas like cancer and infectious diseases, where traditional drug discovery methods have struggled.

Hexagon's approach goes beyond simply screening existing libraries of compounds. Their platform allows them to identify and produce new, previously undiscovered small molecules directly from the vast pool of microbial genomes. They have built a proprietary database of microbial genomes that is significantly larger than any public database and are continuously adding new genomes. This innovative approach, combined with their expertise in synthetic biology and drug discovery, positions Hexagon to lead the way in developing a new generation of therapeutics from nature's untapped potential.

Hexagon Bio is a biopharmaceutical company dedicated to discovering and developing new medicines derived from the global metagenome, the collective genetic material of all microbes and plants on Earth. Their mission is to leverage the power of evolution, using data science, genomics, synthetic biology, and automation to mine microbial genomes for potent small molecules and their protein targets, ultimately translating these discoveries into effective therapeutics for a range of human diseases, with an initial focus on oncology and infectious diseases.

Hexagon Bio fosters a culture of innovation and collaboration, bringing together a diverse team of world experts in their respective fields. They are united by a shared passion for leveraging evolved medicines to improve patient outcomes, encouraging a dynamic and interdisciplinary approach to drug discovery. Their dedication to scientific excellence is evident in their commitment to building a proprietary genomics database, advancing cutting-edge technologies, and developing novel therapeutics.